HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Neutral rating on Minerva Neurosciences (NASDAQ:NERV) and lowers the price target from $7 to $5.
August 07, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao maintains a Neutral rating on Minerva Neurosciences and lowers the price target from $7 to $5.
The lowered price target from $7 to $5 by HC Wainwright & Co. suggests a less optimistic outlook for Minerva Neurosciences, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100